Fig. 1

Flow diagram demonstrating the methods used for the identification of patients to retrospectively assess the efficacy and safety of cetuximab (CET) versus bevacizumab (BEV) following prior 12 cycles of FOLFOXIRI plus BEV in postmenopausal women with advanced KRAS and BRAF wild-type (wt) colorectal cancer (CRC)